SIS
ALNY icon

Sound Income Strategies’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sound Income Strategies’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-56
Closed -$18.4K – 554
2026
Q1 		$18.4K Sell
56
-5
-8% -$1.7K ﹤0.01% 1224
2025
Q4 		$21.9K Buy
+61
New +$27K ﹤0.01% 1110

Other funds holding ALNY

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
FAF
Fjarde Ap-fonden Stockholm, Sweden $20.9B AUM 36.93% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Sound Income Strategies's ALNY Position: Q2 2026 in Review

Sound Income Strategies sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 56 shares — an estimated $18.4K sold.

Sound Income Strategies first reported a position in ALNY in Q4 2025 and held it in 2 quarters. The position peaked at $21.9K in Q4 2025. 247 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Sound Income Strategies reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Sound Income Strategies sold 56 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $18.4K.
  • Sound Income Strategies first reported a position in Alnylam Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Sound Income Strategies's Alnylam Pharmaceuticals position peaked at $21.9K in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.